Tripeptides, E.g., Tripeptide Thyroliberin (trh), Melanostatin (mif), Etc. Patents (Class 530/331)
  • Patent number: 10238771
    Abstract: Methods for treating a bioprosthetic tissue are described herein. The methods comprise contacting the bioprosthetic tissue with at least one nucleophile and/or at least one electrophile in the presence of a catalytic system comprising at least one or a combination of a fluoride-based salt, a cesium-based salt, a potassium-based salt, a rubidium-based salt, or a carbonate-based salt. The methods may be used to alter functional groups on biological tissue which represent actual and potential calcium binding sites and also processes for cross-linking bioprosthetic tissue. Both processes may be used in conjunction with known fixative techniques, such as glutaraldehyde fixation, or may be used to replace known fixative techniques.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: March 26, 2019
    Assignee: Edwards Lifesciences Corporation
    Inventors: Dengfeng Xu, Jeffrey S. Dove
  • Patent number: 10231917
    Abstract: The invention is directed to the use of at least one peptide of formula: X—(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: —n=0, 1 or 2; —m=0 or 1 and if m=0 then n?0-Xaai is: —An hydrophobic amino acid; —A polar amino acid; —or Glycine (Gly, G); When n=2 the two amino acids Xaa1 can be the same or different; —Xaa2 is: —An hydrophobic amino acid; —A basic amino acid Glycine (Gly, G) or Serine (Ser, S); —At the N terminal end of the peptide, X is selected from H, —CO—R1 and —SO2—R1; —At the C terminal end of the peptide, Y is selected from OH, OR1, NH2, NHR1 or NR1R2, R1 and R2 being independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group; Excluding the peptides where X=H and Y=OH, for a non therapeutical cosmetic pro-pigmenting treatment of skin.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: March 19, 2019
    Assignee: Sederma
    Inventors: Olivier Peschard, Philippe Mondon
  • Patent number: 10072043
    Abstract: Disclosed herein are compounds that selectively inhibit members of the PTP family of enzymes. Synthesized compounds demonstrated selective inhibition of TC-PTP. Also provided are methods of using the compounds and formulations containing the compounds. Also described is a fluorescence-tagged combinatorial library synthesis and screening method. And methods of using these compounds to effect enzyme activity both in cells and in vitro as well as method of using these compounds to treat diseases in human and animals.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: September 11, 2018
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Zhong-Yin Zhang, Sheng Zhang
  • Patent number: 9562069
    Abstract: The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: February 7, 2017
    Inventors: Jan-Eric Ahlfors, Khalid Mekouar
  • Patent number: 9540346
    Abstract: The disclosure provides crystalline Sovaprevir forms. The crystalline forms of Sovaprevir comprise a Form A polymorph, a Form B polymorph, a Form C polymorph, a Form D polymorph, and a Form E polymorph. The Form A, B, C, D, and E polymorphs exhibit X-ray powder diffraction patterns having peak locations in accordance with FIGS. 1, 4, 7, 10, and 13, respectively.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 10, 2017
    Assignee: ACHILLION PHARMACEUTICALS, INC.
    Inventor: Avinash Phadke
  • Patent number: 9482673
    Abstract: The present invention relates to a chromogenic method for simultaneously determining the activity of multiple coagulation proteases or for simultaneously determining the inhibition of multiple coagulation proteases in a single test reaction. For this purpose, use is made of two chromogenic substrates which have different absorption maxima and whose color signals can be separated spectrally.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: November 1, 2016
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventor: Norbert Zander
  • Patent number: 9421237
    Abstract: The present invention discloses proteasome inhibitors of tripeptide boronic acids or boronic esters represented by Formula (I), preparative method and use thereof. The proteasome inhibitors are therapeutical agents for treating malignant tumor, various nervous system degenerative diseases, muscle cachexia or diabetes, wherein the malignant tumor is leukemia, gastric cancer, hepatocarcinoma or nasopharyngeal carcinoma.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: August 23, 2016
    Assignee: PEKING UNIVERSITY
    Inventors: Runtao Li, Jingrong Cui, Yongqiang Zhu, Shuyang Yao, Zemei Ge, Tieming Cheng
  • Patent number: 9353147
    Abstract: The present invention provides a production method of peptide, which includes the following step (1). (1) removing N-terminal Fmoc group of N-Fmoc C-protected amino acid or N-Fmoc C-protected peptide wherein a C-terminal carboxy group is protected by an anchor group derived from an anchor soluble in halogenated solvents or ether solvents, insoluble in polar solvents and having a molecular weight of not less than 300, with a non-nucleophilic organic base in a halogenated solvent or ether solvent to give a C-protected amino acid or C-protected peptide, neutralizing with an acid, adding N-Fmoc amino acid or N-Fmoc peptide, a condensing agent and a condensation accelerator to the reaction solution after neutralization, and condensing the N-terminal of the C-protected amino acid or C-protected peptide with N-Fmoc amino acid or N-Fmoc peptide to give an N-Fmoc C-protected peptide.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: May 31, 2016
    Assignee: AJINOMOTO CO., INC.
    Inventor: Daisuke Takahashi
  • Patent number: 9227995
    Abstract: A peptide which can adopt a 310-helical conformation in which the side chains of two amino acid residues in the peptide backbone are linked by a group comprising an aromatic 5-membered ring.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: January 5, 2016
    Assignees: DRUG DISCOVERY LABORATORY AS
    Inventors: Øyvind Jacobsen, Pål Rongved, Jo Klaveness
  • Patent number: 9226974
    Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: January 5, 2016
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Heng Cheng, Sanjeev Gangwar, Qiang Cong
  • Patent number: 9133501
    Abstract: The present invention relates to a method for detecting at least one direct factor Xa inhibitor in a sample other than citrate plasma, comprising the step of mixing a sample containing a factor Xa inhibitor with a composition containing factor Xa under conditions which allow the factor Xa to release a detectable substance from a chromogenic substrate.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: September 15, 2015
    Assignee: Ruprecht-Karls-Universität Heidelberg
    Inventors: Job Harenberg, Roland Krämer
  • Publication number: 20150140139
    Abstract: The present invention relates to a composition for improving or promoting hair growth, which contains, as an active ingredient, a photosensitizer-peptide conjugate, and to a method for screening for the hair growth promoter using the active ingredients. ALA, which is the photosensitizer of the present invention, is preferably activated by LED radiation, and more preferably activated by radiation having a long wavelength of 650 to 675 nm. The peptide of the present invention is a peptide in which 3 to 7 amino acid residues are incorporated (most preferably, glycine-histidine-lysine), and may cooperate with the photosensitizer to enable very superior hair growth improving or promoting effects using light radiation. Further, the composition of the present invention may exhibit further superior effects when natural extracts (for example, Cimicifuga heracleifolia extracts, Scutellaria baicalensis extracts or Codonopsis lanceolata extracts) are added.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 21, 2015
    Inventors: Darren Williams, Da-Won Jung, Soon-Ho Yim
  • Publication number: 20150132440
    Abstract: A composition of dipeptides or tripeptides or ester derivatives may be used as a nutritional supplement and to modulate expression of genes associated with healthy maintenance and regulation of muscular and neurological tissue. The compositions include dipeptides and/or tripeptides of branched chain amino acids and optionally include adjuvants, anti-aging compounds and may be provided in a dissolvable powder or liquid form.
    Type: Application
    Filed: August 13, 2014
    Publication date: May 14, 2015
    Inventor: John H Owoc
  • Publication number: 20150126708
    Abstract: The present invention provides a method of radio fluorination of biological targeting molecules (BTMs) with the radioisotope 18F. Also provided are novel conjugates useful in the 18F-radio fluorination method, and the use of such conjugates and automated synthesizer apparatus including cassettes for carrying out the method.
    Type: Application
    Filed: December 20, 2012
    Publication date: May 7, 2015
    Applicants: IMPERIAL INNOVATIONS LIMITED, GE HEALTHCARE LIMITED
    Inventors: Sajinder Kaur Luthra, Robin Fortt, Ramala Osman Awais, Eric Ofori Aboagye, Graham Smith
  • Publication number: 20150126450
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.
    Type: Application
    Filed: April 16, 2013
    Publication date: May 7, 2015
    Inventors: Kent Kirshenbaum, Paul Michael Levine, Michael John Garabedian
  • Publication number: 20150125422
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 7, 2015
    Inventors: Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola
  • Patent number: 9023801
    Abstract: A topical composition for application to aging skin, including an effective amount of S-acyl glutathione derivative of formula (I) wherein R1 consists of an unsaturated or saturated C16 acyl group and R2 is a hydrogen, aliphatic or aromatic acyl group; and a dermatologically acceptable carrier. Preferred compositions include about 1.0% to about 3.0% by weight of S-palmitoyl glutathione.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: May 5, 2015
    Assignee: N.V. Perricone LLC
    Inventor: Nicholas V. Perricone
  • Publication number: 20150119334
    Abstract: An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.
    Type: Application
    Filed: June 3, 2013
    Publication date: April 30, 2015
    Applicant: Ben-Gurion niversity of the Negev Research and Development Authority
    Inventors: Hanna Rapaport, Anna Gittelman
  • Publication number: 20150119330
    Abstract: Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 30, 2015
    Inventors: Patrick A. McGee, Kenneth W. Jackson, Victoria J. Christiansen
  • Publication number: 20150119553
    Abstract: Compounds are disclosed that are useful for noninvasive imaging in the near-infrared spectral range.
    Type: Application
    Filed: November 24, 2014
    Publication date: April 30, 2015
    Inventors: Xinshe Xu, Daniel R. Draney, Lael Cheung
  • Publication number: 20150119342
    Abstract: The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.
    Type: Application
    Filed: February 20, 2012
    Publication date: April 30, 2015
    Applicants: Universita' Degli Studi Di Milano, Fondazione Cariplo, CISI Scrl, Fondazione IRCCS Istituto Nazionale dei Tumori
    Inventors: Pierfausto Seneci, Laura Belvisi, Federica Cossu, Domenico Delia, Carmelo Drago, Daniele Lecis, Stefano Maiorana, Leonardo Pierpaolo Manzoni, Eloise Mastrangelo, Mario Milani de Mayo de Mari, Paola Maria Chiara Perego, Francesca Vasile
  • Publication number: 20150111837
    Abstract: The invention relates to the field of biochemistry and concerns of recombinant method for production of peptides and the resulting peptides. In particular, the invention relates to peptides with the following general formula: A-Thr-Lys-Pro-B-C-D-X, where: A—0, Met, Met (O), Thr, Ala, His, Phe, Lys, Gly B—0, Gly, Asp, Trp, Gin, Asn, Tyr, Pro, Arg C—0, Arg, Phe, Tyr, Gly, His, Pro, Lys D—0, Val, Gly, Tyr, Trp, Phe, His X—OH, OCH3, NH2, where 0 is no amino acid residue, provided that if A?0, then B and/or C and/or D?0, if B?0, then C and/or D?0, excluding the peptides Phe-Thr-Lys-Pro-Gly, Thr-Lys-Pro-Pro-Arg, Thr-Lys-Pro-Arg-Gly.
    Type: Application
    Filed: May 28, 2013
    Publication date: April 23, 2015
    Applicant: "IVIX" Ltd.
    Inventors: Nikolay Fedorovich Myasoedov, Lyudmila Alexandrovna Andreeva, Dmitriy Viktorovich Golikov
  • Publication number: 20150099709
    Abstract: The present invention relates to a use of a compound having ghrelin receptor agonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for treatment of diseases including achlorhydria in which abnormal gastric acid secretion is involved. In addition, the present invention relates to the method of treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agents. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound of the present invention or a pharmaceutically acceptable salt thereof for the treatment of said diseases.
    Type: Application
    Filed: May 27, 2013
    Publication date: April 9, 2015
    Inventors: Nobuyuki Takahashi, Masaki Sudo, Kaoru Shimada, Hiroaki Wakabayashi
  • Patent number: 9000126
    Abstract: Provided is a novel crystal of oxidized glutathione hexahydrate. Crystal of oxidized glutathione hexahydrate is produced by cooling an aqueous solution containing oxidized glutathione to 15° C. or lower to precipitate a crystal of oxidized glutathione hexahydrate.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: April 7, 2015
    Assignee: Kyowa Hakko Bio Co., Ltd.
    Inventors: Ken Kimura, Kenta Fukumoto, Hiroshi Tanaka
  • Publication number: 20150093370
    Abstract: The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 2, 2015
    Inventors: Yoram SHECHTER, Matityahu FRIDKIN
  • Publication number: 20150087578
    Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound for the treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.
    Type: Application
    Filed: August 25, 2014
    Publication date: March 26, 2015
    Inventor: Thomas LUGER
  • Publication number: 20150080316
    Abstract: The invention relates to new functionalized thieno-indole derivatives of formula (I) or (II) which have cytotoxic activity and are useful in treating diseases such as cancer and cellular proliferation disorders. The invention also relates to the use of these functionalized thieno-indole derivatives in the preparation of conjugates.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 19, 2015
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Italo Beria, Michele Caruso, Vittoria Lupi, Paolo Orsini, Matteo Salsa
  • Publication number: 20150080551
    Abstract: There is provided a lysine oligomer derivative, wherein an ?-amino group and a carboxyl group of lysines are linked via a peptide bond, and a group capable of generating or absorbing electromagnetic wave is bonded to a C-terminal carboxyl group, an N-terminal amino group and/or an ?-amino group. This lysine oligomer derivative has the characteristic of specifically accumulating in the cartilage matrix and can generate or absorb an electromagnetic wave, and is, therefore, useful as a cartilage tissue marker.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 19, 2015
    Applicant: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
    Inventors: Toshitaka Oohashi, Hiroki Kakuta
  • Publication number: 20150072942
    Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.
    Type: Application
    Filed: April 8, 2014
    Publication date: March 12, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yu-Ting Ma, Ross L. Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
  • Publication number: 20150073124
    Abstract: The invention provides a microRNA inhibitor that has two or more sequences complementary to the sequence of microRNA to be the target of inhibition, which two or more complementary sequences are linked via one or more linker residues.
    Type: Application
    Filed: March 4, 2013
    Publication date: March 12, 2015
    Inventors: Tadaaki Ohgi, Hisao Shirohzu, Hiroshi Suzuki, Tomohiro Hamasaki, Takayuki Mizutani
  • Publication number: 20150065437
    Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.
    Type: Application
    Filed: March 20, 2014
    Publication date: March 5, 2015
    Applicant: Stealth Peptides International, Inc.
    Inventors: Liping Liu, Lawrence Gu
  • Publication number: 20150064143
    Abstract: The present invention provides an ionically cross-linkable alginate-grafted hyaluronate compound containing alginate and hyaluronate, the alginate and the hyaluronate forming a covalent linkage. The use of the compound can easily provide a cross-linked hyaluronate by adding a divalent cation without using a chemical cross-linking agent. The present invention also provides a method for cell transplantation that includes preparing a composition comprising the compound of claim 1 and cells for transplantation, and administering to a subject in need thereof the composition.
    Type: Application
    Filed: September 3, 2014
    Publication date: March 5, 2015
    Inventors: Kuen Yong LEE, Hong Hyun PARK
  • Publication number: 20150057218
    Abstract: Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 26, 2015
    Inventors: Min ZHONG, Leping LI
  • Publication number: 20150051160
    Abstract: The invention relates to novel tyrosine based linkers that allow the releasable connection of peptides or proteins with other molecular entities, e.g. polyethylene glycol, to processes for their preparation and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.
    Type: Application
    Filed: October 29, 2012
    Publication date: February 19, 2015
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Lop, Sven Wittrock, Ursula Krenz
  • Publication number: 20150051154
    Abstract: The present invention relates to a novel class of alkylating agents comprising a thieno-indole moiety linked to a DNA-binding moiety, which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical composition containing them. The invention also relates to the use of this novel class of alkylating agents in the preparation of conjugates.
    Type: Application
    Filed: March 28, 2013
    Publication date: February 19, 2015
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Italo Beria, Michele Caruso, Vittoria Lupi, Paolo Orsini, Matteo Salsa, Achille Panzeri
  • Publication number: 20150050212
    Abstract: Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 19, 2015
    Inventors: Philip S. Low, Charity Wayua
  • Patent number: 8957025
    Abstract: The present invention relates to dipeptide enkephalin analogues of Formula (I) and their tautomers, ionic forms and pharmaceutically acceptable salts, and their use in medicine, in particular as opioid agonists.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: February 17, 2015
    Assignee: Pfizer Inc.
    Inventor: Dafydd Rhys Owen
  • Patent number: 8957030
    Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: February 17, 2015
    Assignees: Cornell Research Foundation, Inc., Institute de Recherches Cliniques de Montreal
    Inventors: Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao
  • Publication number: 20150045282
    Abstract: Suppository, hot melt and ophthalmic formulations containing amino esters of the formulae (I), (II) and (III), where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof.
    Type: Application
    Filed: August 18, 2014
    Publication date: February 12, 2015
    Inventors: Mahmoud A. ELSOHLY, Waseem GUL, Michael A. REPKA, Soumyajit MAJUMDAR, Mohammad Khalid ASHFAQ
  • Publication number: 20150037268
    Abstract: Provided is niacin-peptide which has skin whitening activity. The peptide of the present invention has skin whitening activity by inhibiting melanogenesis, that is, by inhibiting the expression of a gene related to melanogenesis (for example, TRP-1, TRP2, or MIFT). The peptide of the present invention has high stability and skin permeability. Also provided is a cosmetic composition for skin whitening which contains the niacin-peptide.
    Type: Application
    Filed: August 22, 2012
    Publication date: February 5, 2015
    Inventors: Sung-Ae Choi, Hyuk-Kwang Jeong, Young-Mi Byoun, Jun-Seob Shin, Seo Joon Yoo, Sang-Chul Yoo
  • Publication number: 20150031854
    Abstract: The invention relates to novel hemin derivatives of general formula (I), preparing and use thereof as antibacterial and/or antiviral agents, including, as a component in a pharmaceutical compositions. Advantages of the novel antibacterial and antiviral agents based on the hemin derivatives are in their biocompatibility, biodegradability, a high efficacy against resistant bacteria and widespread viruses which are dangerous to humans, and the lack of toxicity.
    Type: Application
    Filed: November 15, 2012
    Publication date: January 29, 2015
    Applicant: OBSSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES"
    Inventors: Vladimir Evgenievich Nebolsin, Galina Alexandrovna Zheltukhina, Sergei Alexandrovich Okorochenkov
  • Patent number: 8940697
    Abstract: The present invention provides a method of treating, ameliorating or preventing myocardial ischemia/reperfusion injury in a subject in need thereof, by administering to the subject a therapeutically effective amount of an annexin A1 short peptide (ANXA1sp).
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: January 27, 2015
    Assignee: Duke University
    Inventors: Mihai V. Podgoreanu, Zhiquan Zhang, Qing Ma
  • Publication number: 20150023874
    Abstract: The invention described herein pertains to targeted drug delivery conjugates comprising folate receptor ? (FR-?) selective binding ligands and methods for diagnosing, monitoring, and eliminating pathological cells that express FR-?.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 22, 2015
    Inventors: Philip Stewart Low, Balasubramanian Vaitilingam, Venkatesh Chelvam
  • Patent number: 8936781
    Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: January 20, 2015
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Yat Sun Or, Guoqiang Wang
  • Publication number: 20150017192
    Abstract: The present invention relates to methods and reagents for use in site-selective modification of proteins having lysine residues with functionalized peptides using a chemoenzymatic microbial transglutaminase-mediated reaction. The functionalized proteins may be used for study or therapeutic uses.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 15, 2015
    Inventors: Aimee Usera, Zachary Robinson, Jennifer Cobb
  • Publication number: 20150011458
    Abstract: The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).
    Type: Application
    Filed: June 17, 2014
    Publication date: January 8, 2015
    Inventors: Jan-Eric Ahlfors, Khalid Mekouar
  • Publication number: 20150011730
    Abstract: Structural and functional analysis of peptide inhibitor binding to the cyclin D and cyclin A groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Inventors: Campbell McInnes, Shu Liu
  • Publication number: 20150011003
    Abstract: A medium which comprises a fibroblast growth factor (FGF), and a sulfated compound or a pharmaceutically acceptable salt thereof at a concentration which promotes the growth of a stem cell in the presence of FGF, is useful for culturing stem cells.
    Type: Application
    Filed: September 26, 2014
    Publication date: January 8, 2015
    Applicant: AJINOMOTO CO., INC.
    Inventors: Yoko KURIYAMA, Nao SUGIMOTO, Manabu KITAZAWA, Satoru OKAMOTO, Sho SENDA, Ikue HARATA, Satoru OHASHI
  • Patent number: 8927503
    Abstract: The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: January 6, 2015
    Assignee: The University of Queensland
    Inventors: David Paul Fairlie, Ligong Liu, Mei Kwan Yau, Jacky Yung Suen, Robert Reid
  • Publication number: 20150005239
    Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.
    Type: Application
    Filed: June 11, 2014
    Publication date: January 1, 2015
    Inventors: Pablo VILLOSLADA, Angel Messeguer